New drug VT3989 targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This study tests an experimental drug called VT3989, taken daily by mouth, in people with advanced solid tumors, mesothelioma, or non-small cell lung cancer that has stopped responding to standard treatments. The main goals are to check the drug's safety and side effects, and to …
Phase: PHASE1, PHASE2 • Sponsor: Vivace Therapeutics, Inc • Aim: Disease control
Last updated May 04, 2026 16:24 UTC